Table 2.
Patients undergoing pulmonary vein isolation with dabigatran versus warfarin
| Mendoza et al. [16] |
Rowley et al. [17] |
Ellis et al. [18] |
Lakkireddy et al. [19] |
Kaseno et al. [20] |
Snipelisky et al. [21] |
Kim et al. [22] |
Maddox et al. [23] |
Haines et al. [24] |
Bassiouny et al. [25] |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | W | D | W | D | W | D | W | D | W | D | W | D | W | D | W | D | W | D | W | |
| N | 60 | 52 | 113 | 169 | 61 | 110 | 145 | 145 | 110 | 101 | 31 | 125 | 191 | 572 | 212 | 251 | 202 | 202 | 376 | 623 |
| Age (year, mean) | 63 | 64 | 63 | – | – | 60 | 60 | 59 | 62 | 61 | 65 | 61 | 61 | 62 | 63 | 60 | 60 | 59 | 63 | |
| Male (%) | 90 | 88 | – | – | – | – | 79 | 79 | 75 | 79 | 81 | 74 | 80 | 74 | 76 | 67 | 74 | 69 | 75 | 73 |
| Chronic renal insufficiency (%) | – | – | – | – | – | – | 1 | 2 | – | – | ||||||||||
| Creatinine clearance (mL/min, mean) | – | – | – | – | – | – | 97 | 98 | – | – | 81 | 84 | 93 | 93 | ||||||
| Serum creatinine (mg/dL, mean) | – | – | – | – | – | – | 0.9 | 0.9 | 1.0 | 1.1 | 0.9 | 0.9 | ||||||||
| Paroxysmal AF (%) | – | – | – | – | – | – | 57 | 57 | 83 | 55 | 68 | 46 | 53 | 48 | 63 | 57 | 58 | 52 | 57 | 55 |
| CHADS2 score (mean overall) | 1.32 | 1.29 | 1.3 | 1.2 | 0.84 | 1.22 | 1.0 | 1.1 | 0.9 | 0.9 | – | – | ||||||||
| 0 (%) | 34 | 40 | 61 | 46 | 22 | 20 | 43 | 29 | ||||||||||||
| 1 (%) | 43 | 41 | 31 | 41 | 27 | 31 | 37 | 42 | ||||||||||||
| >2 (%) | 23 | 19 | 8 | 14 | 51 | 49 | 21 | 29 | ||||||||||||
| CHADS-Vase score (mean) | – | – | – | – | – | – | 1.6 | 1.5 | – | – | – | – | 1.6 | 1.7 | 1.7 | 1.7 | 1.6 | 1.9 | – | – |
| HAS-BLED score (mean) | 1.47 | 1.63 | – | – | – | – | 1.2 | 1.1 | 0.5 | 0.6 | – | – | 1.0 | 1.1 | – | – | – | – | ||
Single values across treatment groups indicate that only the overall population value was provided. Dashes indicate unreported data
D patients treated with dabigatran, W patients treated with warfarin